Annovis Bio (ANVS) to Post Earnings on Tuesday

Annovis Bio (NYSE:ANVS) will likely be issuing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Annovis Bio to post earnings of ($0.44) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). On average, analysts expect Annovis Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Annovis Bio Stock Performance

NYSE ANVS traded up $0.06 on Tuesday, reaching $1.77. The company’s stock had a trading volume of 204,879 shares, compared to its average volume of 824,148. Annovis Bio has a twelve month low of $1.54 and a twelve month high of $5.50. The firm’s 50 day moving average is $1.81 and its two-hundred day moving average is $2.18. The stock has a market cap of $61.50 million, a PE ratio of -1.04 and a beta of 1.25.

Insiders Place Their Bets

In other Annovis Bio news, Director Michael B. Hoffman bought 76,344 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $1.87 per share, for a total transaction of $142,763.28. Following the acquisition, the director directly owned 3,364,883 shares of the company’s stock, valued at approximately $6,292,331.21. This trade represents a 2.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.80% of the stock is currently owned by company insiders.

Institutional Trading of Annovis Bio

Several institutional investors have recently made changes to their positions in ANVS. JPMorgan Chase & Co. grew its position in Annovis Bio by 69.3% during the second quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company’s stock valued at $32,000 after purchasing an additional 6,100 shares in the last quarter. RKL Wealth Management LLC purchased a new stake in Annovis Bio in the 4th quarter worth approximately $35,000. Wells Fargo & Company MN lifted its position in Annovis Bio by 46.8% in the 4th quarter. Wells Fargo & Company MN now owns 14,307 shares of the company’s stock worth $50,000 after buying an additional 4,561 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Annovis Bio during the 2nd quarter valued at $52,000. Finally, Wealthspire Advisors LLC boosted its stake in shares of Annovis Bio by 100.0% during the 4th quarter. Wealthspire Advisors LLC now owns 20,000 shares of the company’s stock valued at $69,000 after buying an additional 10,000 shares during the period. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Roth Capital initiated coverage on shares of Annovis Bio in a report on Tuesday, July 7th. They issued a “buy” rating and a $8.00 target price on the stock. Weiss Ratings raised Annovis Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Canaccord Genuity Group restated a “buy” rating and issued a $17.00 target price on shares of Annovis Bio in a report on Tuesday, April 14th. Finally, Zacks Research raised Annovis Bio to a “hold” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.67.

About Annovis Bio

Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.

The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients.